Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Individual differences and evidence-based psychopharmacology.

Literature DB >> 23016518

Individual differences and evidence-based psychopharmacology.

Rh Belmaker¹, Yuly Bersudsky, Galila Agam.

Abstract

Individual differences in response to pharmacologic treatment limits the usefulness of mean data obtained from randomized controlled trials. These individual differences exist even in genetically uniform inbred mouse strains. While stratification can be of value in large studies, the individual patient history is the most effective currently available guide for personalized medicine in psychopharmacology.

Entities: Chemical Disease Species

Mesh：

Substances：
Psychotropic Drugs

Year: 2012 PMID： 23016518 PMCID： PMC3523057 DOI： 10.1186/1741-7015-10-110

Source DB: PubMed Journal: BMC Med ISSN： 1741-7015 Impact factor: 8.775

11 in total

1. Risk models and patient-centered evidence: should physicians expect one right answer?

Authors: David M Kent; Nilay D Shah
Journal: JAMA Date: 2012-04-18 Impact factor: 56.272

2. Lithium inhibition of adrenaline-stimulated adenylate cyclase in humans.

Authors: R Ebstein; R Belmaker; L Grunhaus; R Rimon
Journal: Nature Date: 1976-02-05 Impact factor: 49.962

3. Limitations of applying summary results of clinical trials to individual patients: the need for risk stratification.

Authors: David M Kent; Rodney A Hayward
Journal: JAMA Date: 2007-09-12 Impact factor: 56.272

4. Subtyping major depressive disorder.

Authors: Pesach Lichtenberg; R H Belmaker
Journal: Psychother Psychosom Date: 2010-02-20 Impact factor: 17.659

5. Quantifying E. coli proteome and transcriptome with single-molecule sensitivity in single cells.

Authors: Yuichi Taniguchi; Paul J Choi; Gene-Wei Li; Huiyi Chen; Mohan Babu; Jeremy Hearn; Andrew Emili; X Sunney Xie
Journal: Science Date: 2010-07-30 Impact factor: 47.728

6. Valnoctamide as a valproate substitute with low teratogenic potential in mania: a double-blind, controlled, add-on clinical trial.

Authors: Y Bersudsky; J Applebaum; Y Gaiduk; L Sharony; A Mishory; A Podberezsky; G Agam; R H Belmaker
Journal: Bipolar Disord Date: 2010-06 Impact factor: 6.744

7. Homozygote inositol transporter knockout mice show a lithium-like phenotype.

Authors: Yuly Bersudsky; Alona Shaldubina; Galila Agam; Gerard T Berry; Robert H Belmaker
Journal: Bipolar Disord Date: 2008-06 Impact factor: 6.744

8. Quetiapine monotherapy in the treatment of patients with bipolar I or II depression and a rapid-cycling disease course: a randomized, double-blind, placebo-controlled study.

Authors: E Vieta; J R Calabrese; J M Goikolea; S Raines; W Macfadden
Journal: Bipolar Disord Date: 2007-06 Impact factor: 6.744

Individual differences and evidence-based psychopharmacology.

1. Risk models and patient-centered evidence: should physicians expect one right answer?

2. Lithium inhibition of adrenaline-stimulated adenylate cyclase in humans.

3. Limitations of applying summary results of clinical trials to individual patients: the need for risk stratification.

4. Subtyping major depressive disorder.

5. Quantifying E. coli proteome and transcriptome with single-molecule sensitivity in single cells.

6. Valnoctamide as a valproate substitute with low teratogenic potential in mania: a double-blind, controlled, add-on clinical trial.

7. Homozygote inositol transporter knockout mice show a lithium-like phenotype.

8. Quetiapine monotherapy in the treatment of patients with bipolar I or II depression and a rapid-cycling disease course: a randomized, double-blind, placebo-controlled study.

9. Noisy splicing drives mRNA isoform diversity in human cells.

10. Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposal.

1. Lithium nephrotoxicity.

2. Comment on "Lessons from Toxicology: Developing a 21st-Century Paradigm for Medical Research".

3. The Future of Technology in Positive Psychology: Methodological Advances in the Science of Well-Being.